StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30220% above fair value
$133.72+0.91 (+0.69%)

Close on Nov 20, 2026Market cap $329.91BP/E 107.0Yield 2.45%

Merck free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Merck's free cash flow for the twelve months ending Jun 30, 2026 was $16.06B, up 9.1% year over year. For fiscal 2025 it was $12.36B, down 31.7% from the year before. Over ten years it grew 0.9% a year on average. The highest annual figure on record is $18.10B in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.36B-31.7%
FY2024Dec 31, 2024$18.10B+97.9%
FY2023Dec 31, 2023$9.14B-37.8%
FY2022Dec 31, 2022$14.71B+69.6%
FY2021Dec 31, 2021$8.67B+172.1%
FY2020Dec 31, 2020$3.19B-42.2%
FY2019Dec 31, 2019$5.52B-33.6%
FY2018Dec 31, 2018$8.31B+82.1%
FY2017Dec 31, 2017$4.56B-47.9%
FY2016Dec 31, 2016$8.76B-22.2%
FY2015Dec 31, 2015$11.26B+68.7%
FY2014Dec 31, 2014$6.67B-34.0%
FY2013Dec 31, 2013$10.11B+25.3%
FY2012Dec 31, 2012$8.07B-24.3%
FY2011Dec 31, 2011$10.66B+16.6%
FY2010Dec 31, 2010$9.14B+373.5%
FY2009Dec 31, 2009$1.93B-63.4%
FY2008Dec 31, 2008$5.27B-11.9%
FY2007Dec 31, 2007$5.99B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.48B+77.0%
Q1 FY2026Mar 31, 2026$2.93B+149.7%
Q4 FY2025Dec 31, 2025$1.82B-27.4%
Q3 FY2025Sep 30, 2025$6.84B-19.7%
Q2 FY2025Jun 30, 2025$2.53B-47.8%
Q1 FY2025Mar 31, 2025$1.17B-47.4%
Q4 FY2024Dec 31, 2024$2.51B–
Q3 FY2024Sep 30, 2024$8.51B+24.8%
Q2 FY2024Jun 30, 2024$4.85B+76.9%
Q1 FY2024Mar 31, 2024$2.23B+571.4%
Q4 FY2023Dec 31, 2023-$743.00M-122.6%
Q3 FY2023Sep 30, 2023$6.82B+52.3%
Q2 FY2023Jun 30, 2023$2.74B-13.7%
Q1 FY2023Mar 31, 2023$332.00M-91.2%
Q4 FY2022Dec 31, 2022$3.28B-15.6%
Q3 FY2022Sep 30, 2022$4.48B+23.5%
Q2 FY2022Jun 30, 2022$3.17B+216.0%
Q1 FY2022Mar 31, 2022$3.78B+2290.5%
Q4 FY2021Dec 31, 2021$3.89B+96.4%
Q3 FY2021Sep 30, 2021$3.63B+2546.0%
Q2 FY2021Jun 30, 2021$1.00B-25.7%
Q1 FY2021Mar 31, 2021$158.00M–
Q4 FY2020Dec 31, 2020$1.98B–
Q3 FY2020Sep 30, 2020$137.00M-95.8%
Q2 FY2020Jun 30, 2020$1.35B-41.3%
Q1 FY2020Mar 31, 2020-$279.00M-137.7%
Q4 FY2019Dec 31, 2019-$795.00M-129.9%
Q3 FY2019Sep 30, 2019$3.27B+52.7%
Q2 FY2019Jun 30, 2019$2.30B-17.8%
Q1 FY2019Mar 31, 2019$741.00M+5.1%
Q4 FY2018Dec 31, 2018$2.66B-19.4%
Q3 FY2018Sep 30, 2018$2.14B–
Q2 FY2018Jun 30, 2018$2.80B-4.3%
Q1 FY2018Mar 31, 2018$705.00M–
Q4 FY2017Dec 31, 2017$3.30B+7.2%
Q3 FY2017Sep 30, 2017-$1.61B-162.9%
Q2 FY2017Jun 30, 2017$2.92B–
Q1 FY2017Mar 31, 2017-$53.00M–
Q4 FY2016Dec 31, 2016$3.08B–
Q3 FY2016Sep 30, 2016$2.56B–

More Merck figures

See a number that looks wrong?